Caroline Robert
Institut Gustave Roussy
4 papers in the Anchorcite directory, published between 2010 and 2015, cited 31,683 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 4 papers
- Cutaneous Melanoma Detection and Management · 4 papers
- Melanoma and MAPK Pathways · 3 papers
- Immunotherapy and Immune Responses · 1 paper
Frequent co-authors
- Célèste Lebbé · 3 papers
- Steven J O'Day · 2 papers
- Dirk Schadendorf · 2 papers
- Jessica C. Hassel · 2 papers
- Paul C. Lorigan · 2 papers
- Jedd D. Wolchok · 2 papers
- Jeffrey S. Weber · 2 papers
- Axel Hoos · 2 papers
Papers
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine · 2010 · 15,401 citations
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100)…
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…
- Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations
BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a…
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine · 2011 · 4,600 citations
BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study…
Metadata from OpenAlex (CC0).